Investigators at Duke University Report Findings in Tumor Necrosis Factors (Cd40 Ligand Antagonist Dazodalibep In Sjogren's Disease: a Randomized, Double-blinded, Placebo-controlled, Phase 2 Trial)

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Source:
    Medical Letter on the CDC & FDA. July 21, 2024, 673